Product Description
The module EORTC QLQ-FA13 assesses physical, cognitive, and emotional aspects of cancer-related fatigue. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/28376231/)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Maastricht Radiation Oncology
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01711580 |
12-01-25/01-intern-6810 | N/A |
Withdrawn |
Astrocytoma|Glioblastoma|Glioma |
2015-03-01 |
2019-03-19 |
Treatments |